Michael Anthony White net worth and biography

Michael White Biography and Net Worth

insider of IDEAYA Biosciences

Chief Scientific Officer

Mike is a discovery biologist with over two decades of R&D leadership experience in industry and academia. He has deep expertise in cell regulation, tumor biology, target discovery, technology development and drug discovery.

Mike transitioned from academia to the pharmaceutical industry in 2016 as CSO for Tumor Biology at Pfizer. There he led a cross-disciplinary group to build an oncology small-molecule pipeline focused on first-in-class therapies that intercept oncogenic signaling networks, modulate tumor/host interactions and promote productive anti-tumor immune responses. These efforts culminated in numerous INDs over a span of five years. Prior, Mike was Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center, and inaugural Director of the UTSW Cancer Intervention and Prevention Discovery training program. His appointments include the Hortense and Morton Sanger Professorship in Oncology, the Sherry Wigley Crow Cancer Research Endowed Chair, and the Grant A. Dove Distinguished Chair for Research in Oncology. In 2015, Mike received the inaugural National Institute of Cancer’s Outstanding Investigator Award. He has authored over 150 publications with over 22,000 citations.

Mike completed his postdoctoral training in cancer biology and signal transduction at Cold Spring Harbor Laboratories in New York. He received his Ph.D. in Biology from the University of North Carolina at Chapel Hill, and his B.Sc. (Hons) from the University of Iowa.

How old is Michael Anthony White?: White is currently 58 years old. There are 4 older executives and no younger executives at IDEAYA Biosciences. Learn More on Michael Anthony White's age.
How do I contact Michael Anthony White?: The corporate mailing address for White and other IDEAYA Biosciences executives is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. IDEAYA Biosciences can also be reached via phone at (650) 443-6209 and via email at investor@ideayabio.com. Learn More on Michael Anthony White's contact information.
Has Michael Anthony White been buying or selling shares of IDEAYA Biosciences?: Michael Anthony White has not been actively trading shares of IDEAYA Biosciences during the last quarter. Most recently, Michael Anthony White sold 28,500 shares of the business's stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a transaction totalling $1,032,840.00. Learn More on Michael Anthony White's trading history.
Who are IDEAYA Biosciences' active insiders?: IDEAYA Biosciences' insider roster includes Michael Dillon (SVP), Yujiro Hata (President, CEO & Director), Andres Ruiz Briseno (Senior Vice President, Head of Finance and Investor Relations), Paul Stone (CFO), Jason Throne (insider), and Michael White (insider). Learn More on IDEAYA Biosciences' active insiders.
Are insiders buying or selling shares of IDEAYA Biosciences?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 119,644 shares worth more than $4,832,228.44. The most recent insider tranaction occured on May, 29th when insider Michael Anthony White sold 28,500 shares worth more than $1,032,840.00. Insiders at IDEAYA Biosciences own 3.5% of the company. Learn More about insider trades at IDEAYA Biosciences.
Information on this page was last updated on 5/29/2024.

Michael Anthony White Insider Trading History at IDEAYA Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/29/2024	Sell	28,500	$36.24	$1,032,840.00

Michael Anthony White Buying and Selling Activity at IDEAYA Biosciences

IDEAYA Biosciences Company Overview

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $17.44

$17.05

$18.24

50 Day Range

MA: $21.12

$17.54

$25.10

2 Week Range

Now: $17.44

$16.95

$44.42

Volume

773,034 shs

Average Volume

822,912 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76